Serum Mac-2 binding protein is a novel biomarker for chronic pancreatitis

World Journal of Gastroenterology

Volumn 22, Issue 17, 2016, Pages 4403-4410

  Maekawa, Tomohiro ^a   Kamada, Yoshihiro ^a   Ebisutani, Yusuke ^a   Ueda, Makiko ^a   Hata, Tomoki ^a   Kawamoto, Koichi ^a   Takamatsu, Shinji ^a   Mizutani, Kayo ^a   Shimomura, Mayuka ^a   Sobajima, Tomoaki ^a   Fujii, Hironobu ^a   Nakayama, Kotarosumitomo ^a   Nishino, Kimihiro ^a   Yamada, Makoto ^b   Kumada, Takashi ^c   Ito, Toshifumi ^d   Eguchi, Hidetoshi ^a   Nagano, Hiroaki ^e   Miyoshi, Eiji ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AMs New Otani Clinic   (Japan)

^c OGAKI MUNICIPAL HOSPITAL   (Japan)

^d OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^e YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker; Chronic pancreatitis; Mac 2 binding protein (lgals3bp); Pancreatic ductal adenocarcinoma; Steatopancreatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BINDING PROTEIN; C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GAMMA GLUTAMYLTRANSFERASE; MAC 2 BINDING PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MEMBRANE PROTEIN; TAA90K PROTEIN, HUMAN; TUMOR ANTIGEN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOANALYZER; BIOCHEMICAL ANALYSIS; C REACTIVE PROTEIN BLOOD LEVEL; CHEMILUMINESCENCE IMMUNOASSAY; CHRONIC PANCREATITIS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOLOGY; LIVER INJURY; MAC 2 BINDING PROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREATIC TISSUE; PREDICTION; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL; VOLUNTEER; BLOOD; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; PANCREATITIS, CHRONIC;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIGENS, NEOPLASM; ASPARTATE AMINOTRANSFERASES; BIOMARKERS; C-REACTIVE PROTEIN; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC;

EID: 84970003875     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i17.4403     Document Type: Article

References (30)

1. Sarles H. Definitions and classifications of pancreatitis. Pancreas 1991; 6: 470-474 [PMID: 1876603].
2. Ammann RW. A clinically based classification system for alcoholic chronic pancreatitis: summary of an international workshop on chronic pancreatitis. Pancreas 1997; 14: 215-221 [PMID: 9094150].
3. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Dimagno EP, Andrén-Sandberg A, Domellöf L. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993; 328: 1433-1437 [PMID: 8479461 DOI:10.1056/NEJM199305203282001].
4. Talamini G, Falconi M, Bassi C, Sartori N, Salvia R, Caldiron E, Frulloni L, Di Francesco V, Vaona B, Bovo P, Vantini I, Pederzoli P, Cavallini G. Incidence of cancer in the course of chronic pancreatitis. Am J Gastroenterol 1999; 94: 1253-1260 [PMID: 10235203 DOI:10.1111/j.1572-0241.1999.01075.x].
5. Malka D, Hammel P, Maire F, Rufat P, Madeira I, Pessione F, Lévy P, Ruszniewski P. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002; 51: 849-852 [PMID: 12427788].
6. Tomita Y, Azuma K, Nonaka Y, Kamada Y, Tomoeda M, Kishida M, Tanemura M, Miyoshi E. Pancreatic fatty degeneration and fibrosis as predisposing factors for the development of pancreatic ductal adenocarcinoma. Pancreas 2014; 43: 1032-1041 [PMID: 24991971 DOI:10.1097/MPA.0000000000000159].
7. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30 [PMID: 23335087 DOI:10.3322/caac.21166].
8. Brand RE, Tempero MA. Pancreatic cancer. Curr Opin Oncol 1998; 10: 362-366 [PMID: 9702405].
9. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362: 1605-1617 [PMID: 20427809 DOI:10.1056/NEJMra0901557].
10. Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H, Nakamori S, Monden M, Aozasa K. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 2004; 10: 2846-2850 [PMID: 15102693].
11. Nagata S, Jin YF, Yoshizato K, Tomoeda M, Song M, Iizuka N, Kitamura M, Takahashi H, Eguchi H, Ohigashi H, Ishikawa O, Tomita Y. CD74 is a novel prognostic factor for patients with pancreatic cancer receiving multimodal therapy. Ann Surg Oncol 2009; 16: 2531-2538 [PMID: 19499276 DOI:10.1245/s10434-009-0532-3].
12. Kamada Y, Fujii H, Fujii H, Sawai Y, Doi Y, Uozumi N, Mizutani K, Akita M, Sato M, Kida S, Kinoshita N, Maruyama N, Yakushijin T, Miyazaki M, Ezaki H, Hiramatsu N, Yoshida Y, Kiso S, Imai Y, Kawada N, Takehara T, Miyoshi E. Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis. Proteomics Clin Appl 2013; 7: 648-656 [PMID: 23775887 DOI:10.1002/prca.201200137].
13. Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Mori K, Tanaka S, Yamada M, Akita M, Mizutani K, Fujii H, Yamamoto A, Takamatsu S, Yoshida Y, Itoh Y, Kawada N, Chayama K, Saibara T, Takehara T, Miyoshi E. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. Hepatology 2015; 62: 1433-1443 [PMID: 26199205 DOI:10.1002/hep.28002].
14. Grassadonia A, Tinari N, Iurisci I, Piccolo E, Cumashi A, Innominato P, D'Egidio M, Natoli C, Piantelli M, Iacobelli S. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J 2004; 19: 551-556 [PMID: 14758079 DOI:10.1023/B:GLYC.0000014085.00706.d4].
15. Przybyło M, Martuszewska D, Pocheć E, Hoja-Łukowicz D, Litynska A. Identification of proteins bearing beta1-6 branched N-glycans in human melanoma cell lines from different progression stages by tandem mass spectrometry analysis. Biochim Biophys Acta 2007; 1770: 1427-1435 [PMID: 17600626 DOI:10.1016/j.bbagen.2007.05.006].
16. Artini M, Natoli C, Tinari N, Costanzo A, Marinelli R, Balsano C, Porcari P, Angelucci D, D'Egidio M, Levrero M, Iacobelli S. Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol 1996; 25: 212-217 [PMID: 8878784].
17. Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H. The HCV serum proteome: A search for fibrosis protein markers. J Viral Hepat 2009; 16: 418-429 [PMID: 19226329].
18. Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, Hige S, Sakamoto M, Kage M, Mizokami M, Narimatsu H. A serum " sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep 2013; 3: 1065 [PMID: 23323209 DOI:10.1038/srep01065].
19. Iacovazzi PA, Cozzolongo R, Lanzillotta E, Frisullo S, Guerra V, Correale M. Serum 90K/Mac-2 binding protein (Mac-2BP) as a response predictor to peginterferon and ribavirin combined treatment in HCV chronic patients. Immunopharmacol Immunotoxicol 2008; 30: 687-700 [PMID: 18720164].
20. Abe M, Miyake T, Kuno A, Imai Y, Sawai Y, Hino K, Hara Y, Hige S, Sakamoto M, Yamada G, Kage M, Korenaga M, Hiasa Y, Mizokami M, Narimatsu H. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 2015; 50: 776-784 [PMID: 25326152 DOI:10.1007/s00535-014-1007-2].
21. Shimosegawa T, Kataoka K, Kamisawa T, Miyakawa H, Ohara H, Ito T, Naruse S, Sata N, Suda K, Hirota M, Takeyama Y, Shiratori K, Hatori T, Otsuki M, Atomi Y, Sugano K, Tanaka M. The revised Japanese clinical diagnostic criteria for chronic pancreatitis. J Gastroenterol 2010; 45: 584-591 [PMID: 20422433 DOI:10.1007/s00535-010-0242-4].
22. Ueda M, Kamada Y, Takamatsu S, Shimomura M, Maekawa T, Sobajima T, Fujii H, Nakayama K, Nishino K, Yamada M. Specific increase in serum core-fucosylated haptoglobin in patients with chronic pancreatitis. Pancreatology 2016; pii: S1424-3903(16)00009-0 [PMID: 26897254].
23. Matsumoto H, Shinzaki S, Narisada M, Kawamoto S, Kuwamoto K, Moriwaki K, Kanke F, Satomura S, Kumada T, Miyoshi E. Clinical application of a lectin-antibody ELISA to measure fucosylated haptoglobin in sera of patients with pancreatic cancer. Clin Chem Lab Med 2010; 48: 505-512 [PMID: 20128732 DOI:10.1515/CCLM.2010.095].
24. Kamada Y, Kinoshita N, Tsuchiya Y, Kobayashi K, Fujii H, Terao N, Kamihagi K, Koyama N, Yamada S, Daigo Y, Nakamura Y, Taniguchi N, Miyoshi E. Reevaluation of a lectin antibody ELISA kit for measuring fucosylated haptoglobin in various conditions. Clin Chim Acta 2013; 417: 48-53 [PMID: 23262369].
25. Kobayashi Y, Tateno H, Dohra H, Moriwaki K, Miyoshi E, Hirabayashi J, Kawagishi H. A novel core fucose-specific lectin from the mushroom Pholiota squarrosa. J Biol Chem 2012; 287: 33973-33982 [PMID: 22872641].
26. Kong W, Li S, Longaker MT, Lorenz HP. Cyclophilin C-associated protein is up-regulated during wound healing. J Cell Physiol 2007; 210: 153-160 [PMID: 16998803 DOI:10.1002/jcp.20830].
27. Kong W, Lin BW, Li S, Longaker MT, Lorenz HP. Cyclophilin C-associated protein/Mac-2 binding protein colocalizes with calnexin and regulates the expression of tissue transglutaminase. J Cell Physiol 2010; 223: 151-157 [PMID: 20049854 DOI:10.1002/jcp.22020].
28. Mathur A, Marine M, Lu D, Swartz-Basile DA, Saxena R, Zyromski NJ, Pitt HA. Nonalcoholic fatty pancreas disease. HPB (Oxford) 2007; 9: 312-318 [PMID: 18345311 DOI:10.1080/13651820701504157].
29. van Geenen EJ, Smits MM, Schreuder TC, van der Peet DL, Bloemena E, Mulder CJ. Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. Pancreas 2010; 39: 1185-1190 [PMID: 20871475 DOI:10.1097/MPA.0b013e3181f6fce2].
30. Fock KM, Khoo J. Diet and exercise in management of obesity and overweight. J Gastroenterol Hepatol 2013; 28 Suppl 4: 59-63 [PMID: 24251706 DOI:10.1111/jgh.12407].